Social functioning and quality of life as measures of effectiveness in the treatment of schizophrenia

World Psychiatry

Volumn 8, Issue 1, 2009, Pages 35-36

  Kwon, Jun Soo ^a   Choi, Jung Seok ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; NEGATIVE SYNDROME; NOTE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT COURSE THERAPY; SOCIAL BEHAVIOR; SOCIAL INTERACTION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 62549141434     PISSN: 17238617     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2051-5545.2009.tb00207.x     Document Type: Note

References (11)

1. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and healthy policy. JAMA 2005;290:1624-32.
2. Montes JM, Ciudad A, Gascon J et al. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2005;27:667-74.
3. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsyhotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87.
4. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
5. Rosenheck RR, Perlick D, Bingham S et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-702.
6. Endicott J, Nee J, Harrison W et al. Quality of life enjoymem and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6.
7. Ritsner M, Gibel A, Perelroyzen G et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24:582-91.
8. Merlo MC, Hofer H, Gekle W et al. Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 2002;63:885-91.
9. Mortimer A, Martin S, Loo H et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63-9.
10. Strakowski SM, Johnson JL, Delbello MP et al. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res 2005;78:161-9.
11. Kane J, Canas F, Kramer M et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61.